Brokers Set Expectations for NAGE Q3 Earnings

Key Points

• Analysts at Roth Capital projected Niagen Bioscience's Q3 2025 earnings at $0.01 per share, with a forecast of $0.25 EPS for FY2027.
• The stock currently holds an average rating of "Moderate Buy" with a target price of $13.42, following various ratings adjustments by different equities analysts.
• Recently, Silverberg Bernstein Capital Management acquired 125,262 shares of Niagen Bioscience, reflecting a strong institutional interest in the company.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Research analysts at Roth Capital issued their Q3 2025 earnings per share estimates for shares of Niagen Bioscience in a research report issued on Tuesday, October 7th. Roth Capital analyst S. Mcgowan expects that the company will earn $0.01 per share for the quarter. Roth Capital also issued estimates for Niagen Bioscience's FY2027 earnings at $0.25 EPS.

A number of other equities analysts have also recently issued reports on the company. Wall Street Zen cut Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Tuesday, September 9th. HC Wainwright upped their price objective on Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a research note on Monday, August 11th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Niagen Bioscience in a research report on Saturday, September 27th. Finally, Canaccord Genuity Group boosted their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Niagen Bioscience currently has an average rating of "Moderate Buy" and an average target price of $13.42.

Niagen Bioscience Price Performance

NAGE opened at $7.18 on Wednesday. The firm has a 50 day simple moving average of $9.47 and a 200 day simple moving average of $9.55. The company has a market cap of $572.61 million, a price-to-earnings ratio of 34.19 and a beta of 2.13. Niagen Bioscience has a fifty-two week low of $3.18 and a fifty-two week high of $14.69.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. The business had revenue of $31.12 million for the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Institutional Investors Weigh In On Niagen Bioscience

A hedge fund recently bought a new stake in Niagen Bioscience stock. Silverberg Bernstein Capital Management LLC acquired a new stake in Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 125,262 shares of the company's stock, valued at approximately $1,169,000. Silverberg Bernstein Capital Management LLC owned about 0.16% of Niagen Bioscience at the end of the most recent reporting period. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.